Presentation to Ausbiotech Invest 2025
Released
Released
Announcement PDF
AusBiotech Invest 2025
www.avecho.com.au | ASX:AVE
Developing the first pharmaceutical
cannabidiol product for insomnia
Management and Board
Dr Paul Gavin
Chief Executive Officer
Dr Greg Collier
Chairman
Dr Ross Murdoch
Non-Exec Director
Matt McNamara
Non-Exec Director
Kathy Connell
Non-Exec Director
Taken drug from
discovery to approval
Multiple commercial
transactions
Sold Chemgenex to
Cephalon for $230M
CEO of Extractas
Held Executive &
Senior Management
roles at Shire
Pharmaceuticals,
Avecho and Prana
CIO of Biotech Fund
Horizon 3 Healthcare
Previous Executive
roles at BioScience
Managers, SciCapital.
Led ANZ External
Innovation at
Johnson and
Johnson, Sanofi
Executed over $US1B
worth of deals in ANZ
An inventor of the TPM
delivery platform
Developed multiple
TPM enhanced
products to pharma
license
Insomnia is a major
problem worldwide1
Based on the current
global populations up to
237 million
people are affected
of people across the world
experience insomnia
10-30%
$63 billion
Insomnia costs the US economy
each year
1. https://www.thegoodbody.com/insomnia-statistics/
Broadly defined as difficulty initiating or
maintaining sleep
Insomnia can be a symptom of a range of
other disorders, particularly mental health
and psychiatric disorders, and can contribute
to their onset or exacerbation.
Existing medications have safety issues and
significant impairment to next day function
1Sources:
1. https://www.epidiolex.com/
2. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
3. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-gw-pharmaceuticals-plc-creating
4. Suraev, A.S., et al.. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews 2020b (53); 101339
Cannabidiol (CBD) is the major non-psychoactive
component of medicinal cannabis
Only one pharmaceutical CBD product is approved
by the FDA (Epidiolex®)1
• Epidiolex was developed by GW Pharma
• Approved for rare childhood epilepsy conditions2
– rarely prescribed
• GW Pharma was acquired for $7.2Bn USD by
Jazz Pharma (2021) to obtain Epidiolex3
• One of the side effects of Epidiolex is
sleepiness1
Avecho’s TPM increases oral CBD absorption
No pharmaceutical CBD products are approved for sleep, but
insomnia remains one of the most prevalent indications targeted
globally by medical cannabis and consumer CBD products4
Epidiolex®
Avecho’s TPM CBD
Epidiolex® Oil
Avecho’s TPM CBD capsule
Australian TGA Opportunity
› TGA now allows oral CBD products to be
registered as over-the-counter (OTC) medicines1
› OTC medicines are available from a pharmacist
without a prescription, a significant commercial
advantage
› Australians spend ~$5B per year on OTC
medicines2
› Avecho met with TGA in 2024 to discuss our
Phase III protocol and future submission plans.
TGA had no requested changes.
Sources:
1. https://www.tga.gov.au/news/media-releases/over-counter-access-low-dose-cannabidiol
2. Medicines in the health system, Australian Institute of Health and Welfare (2022)
› Largest randomized, placebo-controlled trial in the
world assessing CBD for insomnia
› Developed using FDA and EMA guidance documents
› Targeting 519 patients; 210 to interim analysis
› 160 patients on study medication: ~50 required
› Interim read-out expected H1 2026
Ongoing phase 3 Trial
Major inflection point for Avecho
Globally
Forecast market size
It affects 10-30% of the population, with 10-
15% of the population classified as chronic1,2
9.5M
people in Australia
experience symptoms
of insomnia
3.6M
people in Australia
classified as
chronic insomniacs
Initial forecasts for OTC CBD in Australia are
>$US 125M per year3
Big Business: Global insomnia market
was valued at $US 5.22B in 20244
Global mental health market valued at
$US 375.2B in 20225
4. https://www.marketresearchfuture.com/reports/insomnia-market-
545#:~:text=How%20much%20is%20the%20insomnia,forecast%20period%2C%20
2024%2D2032.
5. https://finance.yahoo.com/news/532-billion-mental-health-market-144800771.html
1. https://www.deloitte.com/au/en/services/economics/analysis/rise-try-to-shine.html
2. The societal and economic burden of insomnia in adults: An international study, RAND, 2023
3. Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021
* Calculated based on volumes sold, the daily dose as defined
by the World Health Organisation, the treatment duration and
certain adjustments from internal medical experts
^. AAM as data source for US healthcare
system savings; IQVIA Midas data source
for EU healthcare system savings
#. Based on 2023 WifOR Institute analysis
1. Sandoz Integrated Annual Report 2023. Available from:
https://prod.cms.sandoz.com/sites/spare53_sandoz_com/files
/Media%20Documents/2023-Integrated-Annual-Report.pdf.
P.3365. (accessed April 2024)
Swiss-based multinational
pharmaceutical company spun out of
Novartis (Market Cap ~$US 26Bn)
• Global presence
• Portfolio of ~1,500 approved
medicines
• Annual revenues >$US 10Bn
• >800 million patient treatments
annually
Licensing Deal
• Sandoz acquired exclusive rights to Avecho’s
pharmaceutical cannabidiol capsule for insomnia in
Australia (ROFR ROW) March 20252
• Avecho to receive upfront, milestone and royalty payments:
$US 3M
(~A$4.8M) up
front payment
received upon
signing
$US 16M
(~A$24.4M) in
development
milestones prior to
commercial sales
Tiered royalties
ranging from
14% to 19%
on net sales
• Sandoz to purchase the product from Avecho for commercial
sale
Sources:
2. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02920239-3A663194&v=undefined
Commercial
Growth
› Commercial validation from multinational
pharmaceutical company
› Australia the first territory in a global strategy
› Licensing deal marks the first of potentially
several agreements globally
USA 30x
Europe 20x
China 10x
LATAM 4x
Canada 1.5x
MENA 2x
Japan 5x
Partnered
Australia is small compared to international pharmaceutical
markets. Huge opportunity for overseas territories
US $19M*
*For upfront and potential milestone
payments prior to commercial sales1
1. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02920239-3A663194&v=undefined
Pharma deal for Australia
Commercial Launch
TGA
Complete
Major stackable inflection points
Phase III Interim Analysis
Phase III Completion
Deals for global territories
TGA Submission and Approval
Commercial Launch Australia
The path ahead
Development/submission for ROW (FDA, EMA, etc)
H1 2026
Discussions
ongoing
27/28*
2028*
26/27
Significant re-rate anticipated with
positive interim results
*Indicative timeline estimates, reliant on time to Phase 3 completion and duration of TGA review
Questions Welcome
Dr Paul Gavin
Chief Executive Officer
T. +61 3 9002 5000
E. pgavin@avecho.com.au
Melbourne Office
Unit A8, 2A Westall Road
Hallmarc Business Park
Clayton VIC 3168
Australia
T: +61 3 9002 5000
E: info@avecho.com.au
Share your feedback
Discover